"Adenoma, Oxyphilic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A usually benign glandular tumor composed of oxyphil cells, large cells with small irregular nuclei and dense acidophilic granules due to the presence of abundant MITOCHONDRIA. Oxyphil cells, also known as oncocytes, are found in oncocytomas of the kidney, salivary glands, and endocrine glands. In the thyroid gland, oxyphil cells are known as Hurthle cells and Askanazy cells.
| Descriptor ID |
D018249
|
| MeSH Number(s) |
C04.557.470.035.140
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Adenoma, Oxyphilic".
Below are MeSH descriptors whose meaning is more specific than "Adenoma, Oxyphilic".
This graph shows the total number of publications written about "Adenoma, Oxyphilic" by people in this website by year, and whether "Adenoma, Oxyphilic" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 2 | 0 | 2 |
| 2008 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2012 | 0 | 2 | 2 |
| 2013 | 0 | 2 | 2 |
| 2019 | 1 | 0 | 1 |
| 2020 | 0 | 1 | 1 |
| 2022 | 1 | 0 | 1 |
| 2025 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Adenoma, Oxyphilic" by people in Profiles.
-
Genomic and Epigenomic Signatures Can Distinguish Aggressive Chromophobe Renal Cell Carcinoma from Indolent Renal Oncocytic Tumors in Clinical-grade Samples. Eur Urol Oncol. 2025 Dec; 8(6):1629-1638.
-
A Rare Case of Synchronous Oncocytoma and Angiomyolipoma of the Kidney. Am J Case Rep. 2022 Mar 01; 23:e935407.
-
Adrenocortical neoplasm of uncertain malignant potential with a myelolipomatous component. BMJ Case Rep. 2020 Jun 11; 13(6).
-
Hybrid oncocytic/chromophobe renal tumors are molecularly distinct from oncocytoma and chromophobe renal cell carcinoma. Mod Pathol. 2019 11; 32(11):1698-1707.
-
Efficacy and tolerability of different starting doses of sorafenib in patients with differentiated thyroid cancer. Oncologist. 2014 May; 19(5):477-82.
-
Hurthle cell carcinoma: an update on survival over the last 35 years. Surgery. 2013 Dec; 154(6):1263-71; discussion 1271.
-
Thyroid lobectomy for indeterminate FNA: not without consequences. J Surg Res. 2013 Sep; 184(1):189-92.
-
Genomic dissection of Hurthle cell carcinoma reveals a unique class of thyroid malignancy. J Clin Endocrinol Metab. 2013 May; 98(5):E962-72.
-
Significance of MDM2 and P14 ARF polymorphisms in susceptibility to differentiated thyroid carcinoma. Surgery. 2013 May; 153(5):711-7.
-
Optimizing therapy for radioactive iodine-refractory differentiated thyroid cancer: current state of the art and future directions. Minerva Endocrinol. 2012 Dec; 37(4):335-56.